RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing ...

Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery ...

(NASDAQ:TNDM), a global insulin delivery and diabetes technology ... by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to ...

Abbott has announced that Tandem Diabetes Care’s t:slim X2 insulin pump has become the first automated insulin delivery (AID) system to integrate with its newly available FreeStyle Libre 2 Plus sensor ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin ...